Novel oral medication muvalaplin lowers Lp(a) in a small international trial

A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of lipoprotein (a), according to late-breaking science presented today at the American Heart Association’s Scientific Sessions 2024. The study is simultaneously published today in JAMA, the Journal of the American Medical Association.